Skip to main content
. 2018 Sep 5;11:48. doi: 10.1186/s13041-018-0392-5

Table 3.

Pathogenic and likely pathogenic mutations adhered to ACMG guidelines in 172 refractory epilepsy children

Case code Gene Gene location Transcript cDNA change Protein change SIFT PP2 MT HSF GERP++ MAF-ExAC MAF-KG Parental Origin ACMG scoring ACMG pathogenicity Diagosis
13 SCN1A chr2–166,901,702 NM_006920 c.1513A > T p.K505X A 6.17 (C) De novo PVS1 + PS2 + PM2 LP DS
23 SCN1A chr2–166,854,657 166,854,660 a [101] NM_006920 c.4331_4334del p.E1444fs De novo PVS1 + PS1 + PS2 + PM2 P DS
26 SCN1A chr2–166,870,270 NM_001165963 c.3689T>C p.L1230P D D D 5.28 (C) De novo PS2 + PM1 + PM2 + PP3 LP DS
35 SCN1A chr2–166,900,287 166,900,288 NM_001165963 c.1934_1935del p.V645fs De novo PVS1 + PS2 + PM2 P DS
38 SCN1A chr2–166,859,121 NM_006920 c.G4112T p.G1371V D P D 5.54 (C) De novo PS2 + PM2 LP DS
53 SCN1A chr2–166,894,306 166,894,337 NM_001165963 c.2895_2926del p.Q965fs Unknown PVS1 + PM2 LP DS
56 SCN1A chr2–166,908,355 a [102] NM_006920 c.838T > C p.W280R D D D 5.41 (C) De novo PS1 + PS2 + PM2 + PP3 P DS
65 SCN1A chr2–166,850,927 NM_006920 c.4549-1G > C splicing D + 5.76 (C) De novo PVS1 + PS2 + PM2 P DS
115 SCN1A chr2–166,848,614 NM_006920 c.5138C > A p.A1713D D D D 5.8 (C) De novo PS2 + PM2 + PP3 LP DS
124 SCN1A chr2–166,848,438 a [103] NM_006920 c.5314G > A p.A1772T D D D 5.69 (C) De novo PS1 + PS2 + PM2 + PP3 P DS
130 SCN1A chr2–166,854,634 166,854,639 a [101] NM_006920 c.4352_4356del p.Y1451Cfs*22 De novo PVS1 + PS1 + PS2 + PM2 P DS
140 SCN1A chr2–166,911,210 166,911,211 NM_006920 c.539delT p.L180X De novo PVS1 + PS2 + PM2 P DS
148 SCN1A chr2–166,901,579 NM_001165963 c.1636G > T p.E546X A 6.17 (C) Unknown PVS1 + PM2 LP DS
149 SCN1A chr2–166,894,430 a [104] NM_006920 c.2769G > A p.M923I D D D 5.18 (C) Paternal PS1 + PM2 + PP3 LP DS
162 SCN1A chr2–166,848,043 166,848,045 NM_001165963 c.5740_5742del p.1914_1914del De novo PS2 + PM2 + PM4 LP DS
172 SCN1A chr2–166,903,330 NM_006920 c.1327G > T p.E443X A 5.31 (C) De novo PVS1 + PS2 + PM2 P DS
93 SCN2A chr2–166,243,416 NM_001040142 c.4712T > C p.I1571T D D D 5.17 (C) De novo PS2 + PM1 + PM2 + PP3 LP OS
55 KCNQ2 chr20–62,073,781 a [105] NM_172107 c.794C > T p.A265V D P D 3.38 (C) De novo PS1 + PS2 + PM2 P OS
90 STXBP1 chr9–130,423,419 a [53] NM_003165 c.364C > T p.R122X A 4.92 (C) Unknown PVS1 + PS1 + PM2 P OS-WS
52 ADSL chr22–40,745,935 NM_000026 c.253C > T p.R85X A 5.59 (C) Maternal PVS1 + PM2 LP WS
chr22–40,742,633 [58] NM_000026 c.71C > T p.P24L T B D 0.153 (N) Paternal PM2 UC
89 KCNT1 chr9–138,651,532 a [106] NM_020822 c.862G > A p.G288S T D D 5.05 (C) De novo PS1 + PS2 + PM1 + PM2 P WS
104 CDKL5 chrX-18,593,592 18,593,593 NM_003159 c.265delT p.F89Lfs*24 De novo PVS1 + PS2 + PM2 P WS
151 STXBP1 chr9–130,428,529 NM_003165 c.748C > T p.Q250X A 5.72 (C) De novo PVS1 + PS2 + PM2 P WS
29 SYNGAP1 chr6–33,393,659 33,393,662 NM_006772 c.274_277del p.G92fs De novo PVS1 + PS2 + PM2 P Doose
164 SLC2A1 chr1–43,396,517 NM_006516 c.296T > G p.M99R D B D 5.51 (C) De novo PS2 + PM2 LP GLUT1-DS
30 MECP2 chrX-153,296,516 a [63] NM_001110792 c.799C > T p.R267X A 3.55 (C) De novo PVS1 + PS1 + PS2 + PM2 P Rett
32 TSC2 chr16–2,126,095 a [91] NM_000548 c.2666C > T p.A889V D D D 5.09 (C) Paternal PS1 + PM2 + PP3 LP TSC
94 TSC2 chr16–2,130,180 a [107] NM_000548 c.3412C > T p.R1138X A 4.74 (C) De novo PVS1 + PS1 + PS2 + PM2 P TSC
TSC2 chr16–2,130,366 a [66] NM_000548 c.3598C > T p.R1200W D D D 4.74 (C) De novo PS1 + PS2 + PM2 + PP3 P
98 TSC2 chr16–2,138,467 NM_001077183 c.5079C > G p.Y1693X D 0.137 (N) Paternal PVS1 + PM2 LP TSC
TSC2 chr16–2,138,465 2,138,466 NM_001077183 c.5077delT p.Y1693fs Paternal PVS1 + PM2 LP
7 SCN8A chr12–52,184,209 a [108] NM_001177984 c.4324G > A p.E1442K D D D 4.68 (C) Paternal PS1 + PM2 + PP3 LP UEE
IQSEC2 chrX-53,263,621 53,263,622 NM_001111125 c.4246_4247insG p.S1416fs De novo PVS1 + PS2 + PM2 P
63 CACNA1A chr19–13,566,019 a [109] NM_001127221 c.301G > C p.E101Q D D D 5.01 (C) De novo PS1 + PS2 + PM1 + PM2 + PP3 P UEE
66 SCN8A chr12–52,200,885 a [110] NM_001177984 c.5492G > A p.R1831Q D D D 4.91 (C) De novo PS1 + PS2 + PM2 + PP3 P UEE
69 PCDH19 chrX-99,551,873 99,551,874 NM_001184880 c.2849-1G > − splicing + Unknown PVS1 + PM2 LP UEE
157 GABRB3 chr15–26,812,802 a [111] NM_021912 c.761C > T p.S254F D D D 6.06 (C) De novo PS1 + PS2 + PM1 + PM2 + PP3 P UEE
160 GABRA1 chr5–161,309,645 a [112] NM_001127648 c.641G > A p.R214H D D D 5.34 (C) De novo PS1 + PS2 + PM1 + PM2 + PP3 P UEE
54 CHD2 chr15–93,540,231 NM_001271 c.3640G > T p.G1214X A 5.64 (C) De novo PVS1 + PS2 + PM2 P UEE
40 VRK2 chr2–58,312,086 NM_001130483 c.C256 + 1G > A splicing D + 5.86 (C) Unknown PVS1 + PM2 LP UE
44 ATP1A2 chr1–160,098,521 NM_000702 c.1097G > T p.G366V D D D 4.77 (C) De novo PS2 + PM1 + PM2 + PP3 LP UE
68 TSC1 chr9–135,772,854 NM_000368 c.2768_2769insC p.L924Ffs*26 De novo PVS1 + PS2 + PM2 P UE
79 SLC9A6 chrX-135,080,322 135,080,336 NM_001042537 c.582_595del p.Y194fs De novo PVS1 + PS2 + PM2 P UE

Abbreviations: M male, F female, m month, y year, SIFT Sorts intolerant from tolerant (D, damaging; T, tolerant), PP2, polymorphism phenotyping v2 (D, damaging; P, possible damaging; B, benign), MT mutation taster (D, disease causing; A, disease causing automatic), HSF human splicing finder (+, altering splicing), GERP++ genomic evolutionary rate profiling (C, conserved; N, nonconserved), KG 1000 Genomes project, LP likely pathogenic, P pathogenic, DS Dravet syndrome, OS Ohtahara syndrome, OS-WS OS syndrome evolves to West syndrome, WS West syndrome, Doose Doose syndrome, GLUT1-DS glucose transporter type 1 deficiency syndrome, Rett Rett syndrome, TSC tuberous sclerosis complex, UEE unclassified epileptic encephalopathy, UE unclassified refractory epilepsy

a Mutations have been reported in HGMD database